Document is current

Article History

Received: 4 August 2020

Accepted: 3 April 2021

First Online: 16 April 2021

Declarations

:

: Not applicable.

: The study was approved by the University of Arkansas for Medical Sciences Institutional Review Board, protocol #135,176. All subjects provided informed consent.

: Not applicable.

: Dr. Coker has received support from the Brain and Behavior Research Foundation, National Institute on Drug Abuse, Arkansas Children’s Research Institute, and the UAMS Translational Research Institute (UL1TR000039). She has served as a non-compensated physician on clinical trials for Janssen Pharmaceuticals and Boeringer Ingelheim. Dr. Ray-Griffith receives support from the Translational Research Institute, grants <b>UL1TR000039</b> and <b>KL2TR000063</b> through the NIH National Center for Research Resources and the National Center for Advancing Translational Sciences. Dr. Kearns is a consultant in pediatric clinical pharmacology for American Regent, Inc. and work involves the design of early-phase drug trials for conduct in pediatric populations, and is also a consultant in pediatric clinical pharmacology for Boeringer Ingelheim and work involves the design of early-phase drug trials for pediatric populations. Dr. Stowe has received research support from NIH, GSK, Pfizer, Wyeth, Janssen, and SAGE; has served on speaker advisory boards for Pfizer, Eli Lilly, Wyeth, BMS, and GSK; and has received honoraria from Eli Lilly, GSK, Pfizer, and Wyeth. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. None of the work in this article was funded through our influence in the above disclosed conflicts.